Increasing Transparency in Generic Drug Applications Act

United States117th CongressS-4338Senate
Updated: May 26, 2022

Summary

Increasing Transparency in Generic Drug Applications Act This bill requires the Food and Drug Administration to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why).

Bill texts

Available versions
Introduced (Senate)View official text

1 version available

All available records shown.

Timeline

  1. Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

    Senate

  2. Introduced in Senate

All available records shown.